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ABSTRACT
Objectives: Children with Crohn’s disease grow
poorly, and inflammation depresses the response of
insulin-like growth factor-1 (IGF-1) to growth hormone.
Correcting the inflammation normalises growth
velocity; however, removing inflammation cannot be
achieved in all children. Our lack of understanding of
IGF-1 kinetics has hampered its use, particularly as
high IGF-1 concentrations over long periods may
predispose to colon cancer. We hypothesised that
mathematical modelling of IGF-1 would define dosing
regimes that return IGF-1 concentrations into the
normal range, without reaching values that risk cancer.
Design: Pharmacokinetic intervention study.
Setting: Tertiary paediatric gastroenterology unit.
Participants: 8 children (M:F; 4:4) entered the study.
All completed: 5 South Asian British; 2 White British; 1
African British. Inclusion criteria: Children over
10 years with active Crohn’s disease (C reactive protein
>10 mg/l or erythrocyte sedimentation rate >25 mm/h)
and height velocity <–2 SD score. Exclusion criteria:
closed epiphyses; corticosteroids within 3 months;
neoplasia or known hypersensitivity to recombinant
human IGF-1 (rhIGF-1).
Interventions: Subcutaneous rhIGF-1 (120 μg/kg) per
dose over two admissions: the first as a single dose
and the second as twice daily doses over 5 days.
Primary outcome: Significant increase in circulating
IGF-1.
Secondary outcomes: Incidence of side effects of
IGF-1. A mathematical model of circulating IGF-1 (Ac)
was developed to include parameters of endogenous
synthesis (Ksyn); exogenous uptake (Ka) from the
subcutaneous dose (As): and IGF-1 clearance: where
dAc/dt=Ksyn − Kout×Ac+Ka×As.
Results: Subcutaneous IGF-1 increased concentrations,
which were maintained on twice daily doses. In covariate
analysis, disease activity reduced Ksyn (p<0.001). Optimal
dosing was derived from least squares regression fitted to
a dataset of 384 Crohn’s patients, with model parameters
assigned by simulation.
Conclusions: By using age, weight and disease activity
scaling in IGF-1 dosing, over 95% of children will have
normalised IGF-1 concentrations below +2.5 SDs of the
normal population mean, a level not associated with
cancer risk.
INTRODUCTION
A quarter of cases of Crohn’s disease now
present in children and adolescents under
18 years1 2 and its incidence in childhood is
increasing.3 Around one third of the chil-
dren experience linear growth retardation,
ARTICLE SUMMARY
Article focus
▪ One-third of the children with Crohn’s disease
have growth retardation.
▪ Children with active inflammation have insensitiv-
ity to growth hormone, resulting in low circulat-
ing insulin-like growth factor-1 (IGF-1).
▪ There is no agreed growth therapy for children
whose inflammation is intractable to treatment,
because very high and sustained IGF-1 concen-
trations are a risk factor for colon cancer in
adults with acromegaly.
Key messages
▪ IGF-1 can be restored to the normal range by
subcutaneous injections.
▪ The endogenous synthesis of IGF-1 depends on
Crohn’s disease activity variations in both deter-
mine the circulating IGF-1 concentrations.
▪ A new mathematical model which incorporates
disease activity (in addition to weight and age)
will allow paediatric gastroenterologists to calcu-
late doses that keep the circulating IGF-1 in the
upper normal range.
Strengths and limitations of this study
▪ Using the mathematical model, IGF-1 can be pre-
scribed in doses that do not increase the risk of
cancer.
▪ For the first time, long-term IGF-1 treatment can
be studied in children to determine if it enhances
growth and this is a critical step in offering a
therapy (much demanded by patients) for growth
retardation in children with Crohn’s disease.
▪ A limitation of the study is that long-term studies
over several years will still be required on a large
group of children.
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caused in part by undernutrition and in part by the
direct effects of inﬂammation on growth.4
Growth in childhood is regulated by growth hormone
(GH), secreted from the pituitary, which stimulates the
production of insulin-like growth factor-1 (IGF-1) by the
liver and growth plates of bones.5 Children with active
Crohn’s disease have low circulating IGF-1 and increased
circulating cytokines.6 7 Treatment of the inﬂammation,
for example, by an enteral diet, results in a reduction in
cytokines like IL-6 and an increase in IGF-1 within 3 days.7
Thus, the optimum treatment for improving growth is to
eliminate the inﬂammation. Nevertheless, some children’s
inﬂammation remains intractable to treatment despite the
best efforts of clinicians. For this group, there is currently
no agreed therapy to enhance growth.
Rats with TNBS-induced colonic inﬂammation grow
poorly8; this is also associated with increased cytokines
IL-6 and TNF and a low circulating IGF-1.9 Exogenous
IGF-1 given to the rats with colitis enhanced their
growth.8 In transgenic mice, without inﬂammation, high
levels of circulating IL-6, generated by a widely acting
promoter, depressed both IGF-1 and growth.10 Thus, the
link between inﬂammatory cytokines, IGF-1 and poor
growth is strong.11 There is a functional insensitivity to
GH in children with Crohn’s disease. Recombinant
IGF-1 is now a recognised therapy for children with GH
insensitivity syndrome (GHIS) due to genetic defects of
the GH receptor or IGF-1 gene12; we therefore hypothe-
sised that IGF-1 concentrations in children with active
Crohn’s disease and poor linear growth could be
restored by administering rhIGF-1.
Restoring IGF-1 in children with Crohn’s disease who
may have some endogenous production is not straight-
forward, because high levels of IGF-1 may be harmful.
For rhIGF-1 to be therapeutically useful, its circulating
levels over the long term should be returned to normal
values by replacement, and not given in excess. Patients
with acromegaly who have very high concentrations
of GH and IGF-1, maintained over decades, have a
doubling in the incidence of colon cancer.13 This
could, in theory, be compounded in children with
Crohn’s disease, as inﬂammation is also a risk factor for
intestinal cancer.
A mathematical model for administration of rhIGF-1,
based on detailed pharmacokinetics would resolve these
difﬁculties, as dosing could be tailored to achieve circu-
lating concentrations that remain within the normal
range. We therefore undertook a careful study of
subcutaneous rhIGF-1 administration in children with
Crohn’s disease-induced growth retardation. We devel-
oped a model which used physiological parameterisa-
tion, disease activity to predict endogenous IGF-1
synthesis and body weight to scale the volume of distri-
bution. Parameters of protein loss, such as protein-losing
enteropathy, were also considered. The model was used
to recommend dosing which allows children to be
treated with rhIGF-1 without its concentration rising
above the normal range.
METHODS
Patient selection
Following ethical approval from the East London & City
Research Ethics Committee (reference number
07/H0705/77) and regulatory approval from the UK
Medicines and Healthcare products Regulatory Agency
(Eudract number: 2007-004269-16), written informed
consent was obtained from the parents and patients
attending the paediatric inﬂammatory bowel disease
clinic at Barts and The London Hospital for Children.
Inclusion criteria were age ≥10 years; known Crohn’s
disease diagnosed by endoscopic, histological and radio-
logical methods;14 a height velocity measured over at
least a 6-month period of <–2 SD Score (SDS) according
to the patient’s age and gender; and an evidence of
active inﬂammation as demonstrated by either an
erythrocyte sedimentation rate (ESR) >25 mm/h and/or
a C reactive protein (CRP) >10 mg/l. Exclusion criteria
were corticosteroid use in the preceding 3 months;
active or suspected neoplasia; known hypersensitivity to
exogenous rhIGF-1 (Increlex, Ipsen UK); and the pres-
ence of closed epiphyses.
All patients had a full history and physical examination,
including an accurate recording of height, weight and
assessment of pubertal status. In addition, they also had
an ECG and faecal α1-antitrypsin levels (g/l) measured.
Study design
Exogenous rhIGF-1 was administered by subcutaneous
injection at doses of 120 µg/kg over two admissions.
Admission 1 investigated the effects of a single dose of
rhIGF-1 over a 24 h inpatient stay. Baseline blood
screens included full blood count (FBC), electrolytes,
inﬂammatory markers (CRP and ESR), baseline IGF-1,
IGFBP-3, acid labile subunit (ALS) and blood sugar.
The Pediatric Crohn’s Disease Activity Index (PCDAI)
was calculated.15 16
Each patient was then given a single subcutaneous
injection of rhIGF-1 at a dose of 120 µg/kg. Serial
venous blood samples were drawn at the following time
points: 0, 1, 2, 3, 4, 6, 12, 17 and 24 h. Blood sugars and
vital signs were checked regularly. Children ate and
drank freely, and continued to receive their prescribed,
non-corticosteroid treatment for Crohn’s disease.
Following a wash out of at least 3 months, the partici-
pants were readmitted for admission 2, investigating the
effects of repeated doses of rhIGF-1. On this occasion,
six doses of rhIGF-1 were administered over a 5-day trial
period, with doses given at 0, 12, 72, 84, 96 and 108 h.
The injection sites were rotated according to the
patient’s wishes. Serial blood samples for further IGF-1,
IGFBP-3, ALS and blood sugar were collected during
the 5 days at 0, 1, 2, 3, 4, 6, 12, 17, 24, 48, 72, 96 and
120 h. Additional samples were also taken for clinical
reasons when there was a possibility of hypoglycaemia. If
sufﬁcient sample was collected, IGF-1 levels were also
measured. In addition, vital signs, FBC, electrolytes and
inﬂammatory markers were measured daily. Patients
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were kept as inpatients during the days that the rhIGF-1
was administered, but were allowed home during the
2 days in which they received no injections. Patients were
discharged home on day 6.
Assays and samples
All samples were stored at −20°C until analysis. Plasma
glucose was determined immediately after blood sampling
(Beckman Instruments, Palo Alto, California, USA).
IGF-1 and IGFBP-3
IGF-1 and IGFBP-3 levels were measured by competitive
binding radioimmunoassay (Esoterix Inc Laboratory
Services). The sensitivity of the assay for IGF-1 was
15 ng/ml and the intra-assay coefﬁcient of variation
averaged 14.1%. The sensitivity of the assay for IGFBP-3
was 0.3 mg/l and the intra-assay coefﬁcient of variation
averaged 13%.
Acid labile subunit
ALS levels were measured by radioimmunoassay (ALS-RIA)
using puriﬁed human ALS as tracer. The intra-assay coefﬁ-
cient of variation ranged from 8% to 17.4%.
Mathematical model development
Measured IGF-1 concentrations were ﬁtted for all indivi-
duals simultaneously using the non-linear mixed effects
modelling software NONMEM V.7.1.17 Model building
was undertaken using the ﬁrst-order conditional estima-
tion method with interaction. A turnover model was
used according to the following differential equations:
dAc
dt
¼ Ksyn  Kout  Ac þ Ka  As ð1Þ
dAs
dt
¼ Ka  As ð2Þ
where Ac is the amount of circulating IGF-1 at time t; As
the amount in the subcutaneous tissue following a dose,
with initial conditions adjusted each time a dose is admi-
nistered; Ksyn a zero order production rate of endogen-
ous IGF-1 in µg/h; Kout a ﬁrst-order elimination rate
constant in h−1; and Ka a ﬁrst order absorption rate con-
stant describing exogenous IGF-1 appearance following
a subcutaneous dose in h−1. At steady state prior to
exogenous dose, circulating IGF-1 is given by the ratio of
Ksyn to Kout.
In addition to Ksyn and Ka, the ﬁxed effect parameters
IGF-1 clearance (CL) in l/h and distribution volume
(VD) in litre were estimated, Kout being given by the
ratio of CL to VD. Variability was tested for all parameters
between the participants and residual variability was
described using a heteroscedastic model. Allometric
weight scaling was applied to CL and VD a priori using
linear scaling for VD and weight raised to the power 0.75
for CL,
18 Ksyn was further scaled with linear weight.
Tested covariates were CRP, ESR, PCDAI score and age.
Model development used the NONMEM objective
function value (OFV); parameter estimate precision was
derived through a non-parametric bootstrap19 and
graphical assessment of basic goodness-of-ﬁt plots and
model simulations was undertaken. The OFV is propor-
tional to −2 times the log-likelihood of the data given
the parameter estimates, and a decrease in OFV of 3.84
with 1 degree of freedom gives a signiﬁcantly improved
ﬁt with a probability p<0.05. A utility function based on
the ﬁnal model was used to predict the average concen-
tration (Cave) with a dosing regimen derived from the
integral of the IGF-1 against the time curve divided by
time. Maximum utility was deﬁned as Cave of +0.50 SDS
with linear penalty for deviations above and below this
target. The dose was optimisied to give a model-derived
steady-state Cave by the following model:
Target ¼ SDSiþ1i ð3Þ
Utility ¼
Xn
i¼1 (target  SDSi)
2 ð4Þ
where target is the SDS aim (in this case +0.50); SDSi is
the individual predicted SDS derived from model pre-
dicted CAVE; and ɛi denotes the individual deviations
from the target. Utility is minimised ɛi by least squares
regression.
Demographic details for 384 children aged 8–14 years
from the clinical database were each assigned a random
PCDAI score (from a uniform distribution 0–48) and
also individual model parameters. The utility function
was maximised with either ﬁxed dosing, dosing based
on weight, weight and age, or weight, age and PCDAI
score. Differences in concentrations were explored with
12 and 24 hourly dosing regimens.
Calculation of sample size
The size was derived from the number of children
needed to show a signiﬁcant increase in IGF-1, based on
the increases in IGF-1 seen in a cohort of children with
treated with IGF-1 for GHIS. This showed that in 18 chil-
dren, the concentration before drug was 330 ng/ml
(SEM 20 ng/ml) and the concentration after 4 h was
535 ng/ml (SEM 20 ng/ml). Therefore, to detect a dif-
ference in concentration of 205 (535–330) before drug
and after 4 h and SD of 84.85 (calculated from SE of the
Mean of 20 with sample size of 18), with 80% power at
the 5% level of signiﬁcance, four patients are required.
RESULTS
rhIGF-1 therapy in children with Crohn’s disease
Children with active Crohn’s disease and whose growth
was inhibited were recruited into the study (table 1).
Impairment of height velocity is characteristic of many
children with active Crohn’s disease,4 20–22 and all eight
participants recruited in the study (median age 12.97)
had a height velocity that was more than 2 SDs below
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the mean (ie, a SDS of <–2), as an entry criterion. The
median height velocity SDS was −3.35, indicating
extreme growth failure.
All the participants completed both parts of the study.
The rhIGF-1 was generally well tolerated. Although
subcutaneous rhIGF-1 has been associated with hypogly-
caemia in children treated for GHIS,12 only one patient
(LN01) had a single asymptomatic hypoglycaemic
episode (blood sugar <3.5 mmol/l). This was corrected
with oral glucose. This occurred following the 12 h
dosage of rhIGF-1 during admission 2 in a child who
had not eaten prior to the drug administration. No
further episodes of hypoglycaemia occurred. There were
no other adverse effects.
Determinants of circulating IGF-1
As previously demonstrated, children with Crohn’s
disease-induced growth failure had depressed circulating
IGF-1 concentrations. The severity of disease in any one
child varies over time, and this was reﬂected in the vari-
ation of IGF-1 between the ﬁrst and second admissions,
3 or more months apart (ﬁgure 1A). Despite the vari-
ation both between and within patients, a single subcuta-
neous bolus of rhIGF-1 signiﬁcantly increased IGF-1 in
the circulation (ﬁgure 1). In some cases where the base-
line IGF-1 was less depressed, the post IGF-1 level was
increased to above normal (ﬁgure 1A). The concentra-
tions of IGF-1 returned to baseline over the following
24 h (ﬁgure 1B).
IGF-1 is maintained in the circulation by IGF binding
proteins, the most abundant being IGFBP-3.23 A major
characteristic of Crohn’s disease is protein-losing enter-
opathy, resulting in proteins being lost into the lumen of
the intestine.24 25 We aimed therefore to ascertain if the
degree of protein-losing enteropathy(PLE) blunted the
ability of subcutaneous rhIGF-1 to achieve signiﬁcant
peak concentrations, or if it directly affected IGF
binding proteins. PLE was quantiﬁed by the concentra-
tions of α1-antitrypsin in stool.26 Using this measure,
PLE had no effect on the change in IGF-1 induced by a
subcutaneous injection (ﬁgure 2A).
IGFBP-3 concentrations are depressed in children with
chronic IGF-1 deﬁciency27 and all children in the study
had low IGFBP-3 (ﬁgure 2B). We wished to determine,
however, whether IGFBP-3 concentrations depended on
the degree of PLE, as this would indicate that PLE may
affect IGF-1 pharmacokinetics. However, no association
was observed.
In the second admission, the participants received
twice daily doses, to determine if IGF-1 concentrations
would be enhanced over a longer period. The initial
injection increased the IGF-1 concentrations into the
normal range (ﬁgure 1A). Increases over a sustained
period were successfully achieved (ﬁgure 1C) and as
expected multiple daily dosing led to lower variability
between peak and trough concentrations. Taking the
area under the curve divided by time as the average
IGF-1 concentration, it became clear that on 120 µg/kg,
some children had an average IGF-1 SDS of greater than
+2.5, while other children had appropriate concentra-
tions. Increased circulating IGF-1 in acromegaly has
been linked with an increased risk of colon cancer.13 28
Fortunately, we have a clear understanding of how IGF-1
concentrations relate to colon cancer risk in acromeg-
aly.13 These studies show that the increased cancer risk
was seen in individuals whose circulating IGF-1 was +2.5
SDS or greater. Using our data, we developed a model
from which the dose–concentration relationship could
Table 1 Patient characteristics at recruitment into the trial
Patients
LN01 LN02 LN03 LN04 LN05 LN06 LN07 LN08
Gender F F M M F F M M
Age 13.11 11.5 14.23 10.67 14.82 12.7 12.82 14.66
Ethnicity Caucasian Asian Asian Asian Asian Asian African Caucasian
Tanner stage P1 B1 P1 B1 P3 G3 P1 G1 P2 B2 P2 B2 P2 G2 P1 G1
HV SDS at recruitment −2.11 −2.11 −4.18 −2.83 −2.27 −3.87 −4.43 −4.88
HV SDS at time of trial −2.11 −2.14 −1.84 0.36 1.69 3.55 −4.43 −4.88
PCDAI 12.5 20 17.5 10 47.5 15 12.5 10
Medication 5-ASA 5-ASA 5-ASA
AZA
IFX
5-ASA
AZA
Adalum
5-ASA
AZA
Adalum
5-ASA
AZA
IFX
5-ASA
AZA
5-ASA
Faecal A1AT (g/l) 3.34 0.82 0.88 0.49 2.63 2.28 0.08 0.45
Montreal classification
Disease location L1 L2 L3 L3 L1 L3 L1 L1
Behaviour B1 B1 B3 B3 B2 B1 B2 B1
Upper N N Y N Y Y N N
Perianal N N Y Y N N N N
Tanner stage: P, pubic hair; B, breast stage; G, genitalia. Medications: 5–ASA, 5-aminosalicylic acid; AZA, azathioprine; IFX, infliximab;
Adalum, adalumimab. Montreal classification: L1, ileal; L2, colonic; L3, ileocolonic; B1, non-stricturing, non-penetrating; B2, stricturing;
B3, penetrating.
PCDAI, Pediatric Crohn’s Disease Activity Index; SDS, SD score.
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be derived. We then investigated the covariates on which
dosing could be individualised. This allowed us to
correct circulating IGF-1 without causing excessively
high concentrations: ensuring that our dosing regimens
resulted in concentrations that were below +2.5 SDS, we
developed a utility model to predict the IGF-1 SDS
achieved on regular dosing.
Mathematical modelling of IGF-1 links endogenous
production to disease severity
A turnover model which accounted for both endogenous
production and exogenous dosing of IGF-1 was ﬁtted to
the data (see methods for mathematical formulae) using
non-linear mixed effects analysis. Four ﬁxed effects were
estimated, namely endogenous synthesis rate (KSYN),
exogenous absorption rate through the skin following
subcutaneous injection (Ka), systemic clearance (CL) and
distribution volume VD. Parameter level random effects
(intersubject variability) were included on KSYN and CL
(table 2). A further level of random effects (interoccasion
variability) also provided signiﬁcantly improved ﬁt when
added to KSYN. Following a limited covariate analysis, the
PCDAI score was found to signiﬁcantly improve ﬁt when
added to KSYN, with KSYN falling with increasing disease
severity (ﬁgure 3A). The effect of disease severity as mea-
sured by PCDAI was tested for CL and KSYN with signiﬁ-
cant improvement (p<0.001) being shown for KSYN.
Furthermore, adding the PCDAI score as a covariate to
KSYN allowed interoccasion variability to be removed
without detriment to the model ﬁt (no change in
log-likelihood). Adding PCDAI to KSYN also decreased
interindividual variability. In short, disease severity was a
major driver of IGF-1 synthesis rate both between patients
and in the same patient on different occasions.
Figure 1 Subcutaneous
recombinant human IGF-1
(rhIGF-1) increases the circulating
concentrations of insulin-like
growth factor-1 (IGF-1) in children
with growth failure induced by
Crohn’s disease. (A) IGF-1 SD
scores (SDS) below the normal
range in both first (mean −1.78
(SD 1.37)) and second
admissions (mean −2.34 (SD
0.75)) are significantly increased
a single injection of rhIGF1
(p<0.0005 and <0.0001,
respectively). (B) An injection
reaches a peak within 4 h and
returns to low levels within 24 h.
(C) Twice daily injections of
rhIGF-1 increase circulating IGF-1
over a sustained period. rhIGF-1
was given on day 1 and the
circulating concentrations allowed
to fall, before giving twice daily
injections on days 4 and 5.
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There was good agreement between model predic-
tions and observed concentrations (ﬁgure 3B), and
trendless distribution of standardised residuals, indicat-
ing that the parametric modelling assumptions were sat-
isﬁed (ﬁgure 3C–E). The median of the simulated data
was not signiﬁcantly different to the median of the
observed data (ﬁgure 3F). Superimposing model predic-
tions at a population level and individual level on the
observed data showed that model predictions captured
the dynamic behaviour of the system (ﬁgure 4).
Dosing to maintain circulating rhIGF-1 concentrations
in the target range
We undertook mathematical modelling to quantify the
relationship between endogenous IGF-1 production and
exogenous dosing, and to understand how IGF-1 average
concentrations (area under the curve/time) can be
adjusted. Using the knowledge that in acromegaly there
is no increased risk of cancer in patients whose IGF-1 is
below +2.5 SDS,13 we deﬁned the optimal IGF-1 concen-
tration range as being between 0 and +2.0 SDS. This
range would improve growth without elevating cancer
risk. Different possible dose scaling systems were then
explored to maximise the probability of an individual
having IGF-1 levels in the target range. By individualis-
ing dose by weight, age (because different aged children
have different target circulating IGF-1 levels) and PCDAI
score, 92.7% of children were predicted to be corrected
to less than or equal to +2.0 SDS (95.3% below +2.5
SDS; ﬁgure 5). We can therefore suggest a dosing
scheme that limits the risk of malignancy to that of the
normal patient population. The dosing schedule recom-
mended from the utility function is age 10 to <12 years,
21 µg/kg plus 1 µg/kg /PCDAI point; age 12 to
<14 years, 41 µg/kg plus 1.4 µg/kg /PCDAI point.
DISCUSSION
Impaired growth has been a recognised feature of chil-
dren with Crohn’s disease for 50 years.29 In 1986, low
IGF-1 was associated with poor growth in these chil-
dren30; over the following decade, it was realised that
the depressed concentration was a direct consequence
of inﬂammation,8 10 and not merely the result of poor
energy intake or undernutrition. The best strategy to
increase IGF-1 and therefore to improve growth is the
resolution of inﬂammation. Treatments which reverse
the inﬂammation, but do not actively suppress growth,
Figure 2 Protein-losing enteropathy did not alter insulin-like
growth factor-1 (IGF-1) or IGFBP-3. (A) Variations in
protein-losing enteropathy (as measured by faecal
α1-antitrypsin) did not correlate with changes in IGF-1
concentrations achieved on giving recombinant human IGF-1
(p=0.703). (B) Variations in protein-losing enteropathy did not
correlate with IGFBP-3 concentrations.
Table 2 Parameter estimates from the model including non-parametric 95% CI from a bootstrap of 714 successful runs
Parameter Estimate Bootstrap median
Bootstrap
2.5th percentile
Bootstrap
97.5th percentile
CL (l/h/70 kg) 1.61 1.60 1.36 1.82
VD (l/70 kg) 2.42 2.41 1.78 3.10
KSYN (µg/h) 433 423 352 490
Ka (h−1) 0.10 0.10 0.083 0.12
Coefficient of PCDAI on KSYN −6.57 −6.41 −8.19 −4.89
IIV on CL (%CV) 10.38 9.46 3.49 15.1
IIV on KSYN (%CV) 24.61 24.10 9.98 33.58
Residual error proportional (%CV) 9.81 9.69 7.85 11.04
Residual error, additive (µg/l) 28.32 25.93 13.29 42.78
IIV, interindividual variability; PCDAI, Pediatric Crohn’s Disease Activity Index.
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Figure 3 Insulin-like growth factor-1 (IGF-1) in a mathematical model. (A) Increasing disease activity (Pediatric Crohn’s Disease
Activity Index) significantly (p<0.001) diminishes the estimates of Ksyn in the covariate model building. (B) Population model
predictions versus observed concentrations are unbiased, indicating good structural model fit. (C) Individual model predicted
concentrations are in agreement with observed concentrations. (D) Conditional weighted residuals (CWRES), which are a form of
standardised residuals expected to follow the Normal Independent Distribution (NID; 0,1) lie within −2 and +2 SDs and do not
change with model predictions, indicating good structural model fit. (E) Similarly, the QQ plot of CWRES indicate that the
assumption of normality of residuals is met; (F) Median observed IGF-1 concentrations (solid line) similar to median simulated
(dashed line) and observed median lies within 95% CI of the model simulations (grey-shaded area).
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such as surgery,31 anti-TNF32 33 and enteral diets6 34
have all been shown to improve linear growth.
Nevertheless, there are patients with Crohn’s disease
whose inﬂammation cannot be reversed. In this group,
we need a distinct strategy to accelerate growth. Both
hGH35 36 and rhIGF-1 have been suggested. As patients
with Crohn’s disease have a functional insensitivity to
GH, the present study examined the possibility that
Figure 4 Population level (blue
line) and individual (red line)
model predictions are similar to
observed data (black open
circles) in both (A) single dose
and (B) repeated doses in each
part of the study.
8 Rao A, Standing JF, Naik S, et al. BMJ Open 2013;3:e002737. doi:10.1136/bmjopen-2013-002737
Restoring IGF-1 in children with Crohn’s disease
rhIGF-1 would be efﬁcacious in improving IGF-1 concen-
trations, as it does in children with GHIS. However,
there are signiﬁcant problems in applying our knowl-
edge of rhIGF-1 usage in GHIS to children with Crohn’s
disease. First, children present at a much later age in
Crohn’s disease than they do in GHIS, which is caused
by a genetic mutation (approximately 8–15 years as
opposed to less than 5 years old). The compartments of
the IGF-1 system including several IGF binding proteins
cannot be assumed to distribute as they do in younger
children, particularly if the relative volumes of these
compartments change at the time of puberty. Second,
both IGF-1 and the IGF binding proteins are circulating
proteins. Proteins are lost into the intestine through
PLE, where inﬂammation reduces the ability of the
intestinal vasculature to maintain them in the capillary
lumen.37–39 The PLE could, in theory, alter the kinetics
of IGF-1. Finally, very high and sustained circulating
IGF-1 concentrations are associated with an increase
in colon cancer in middle aged and older patients
with acromegaly. A modelling approach to kinetics
and dosing was necessary to avert causing high average
IGF-1 concentrations.
The reduction in IGFBP-3 raises the question as to
whether giving rhIGF-1 to children with a reduced
IGFBP-3 may increase free IGF-1 concentrations. Since
we did not have access to an assay for free IGF-1, our
data are not totally informative on this issue. However,
they will not have risen to unsafe levels from saturating
the IGF-1 binding capacity. The concentrations of
IGFBP-3 are not greatly depressed in the affected chil-
dren. Even in the most severe case, the IGFBP-3 is
within 2 SDs of normal. In addition, IGF-1 is over 95%
bound to IGF binding proteins, with an excess of
binding capacity. In general, when analysing pharmaco-
kinetic data, the changes in protein binding do not
affect free concentrations, but may affect free fraction.
This means that for two individuals with the same total
concentration, the free concentration maybe elevated in
the one with lower binding protein. However, two indivi-
duals with different IGFBP-3 concentrations given
rhIGF-1 will not achieve the same total concentrations
because as IGF-1 undergoes ﬁrst-order elimination,
higher free concentrations will be more rapidly elimi-
nated due to homeostasis. On analysing our small
dataset, IGFBP-3 was not a signiﬁcant covariate for the
volume of distribution in our model. Indeed, our model
predicts that the majority of patients will have total con-
centrations just above the normal range.
Several children enrolled in the study had delayed
puberty (table 1). Although this is commonly observed
in Crohn’s disease, the study could be criticised for not
taking this into account when calculating IGF-1 SDSs, as
circulating IGF-1 increases in puberty. We do not have
normative data for circulating IGF-1 against pubertal
stage. However, delay in puberty is closely correlated
with a delay in bone age, as measured on a wrist x-ray.
We therefore recalculated each child’s IGF-1 SDS against
their bone age before and after the initial injection of
rhIGF-1 (data not shown). However, this made little dif-
ference to the results obtained when comparing these
data to those based on chronological age (ﬁgure 1A).
Previous studies on rhIGF-1 pharmacokinetics40 41
have mainly focused on its use in malnourished adult
patients with renal failure, where it has been used to
maintain protein balance. These reports undertook
purely descriptive analyses such as area under the
concentration-time curve and comparing healthy volun-
teer parameters with patients, rather than modelling the
data. Furthermore, they did not account for endogenous
IGF-1 production. If we were to use our data to recom-
mend a dose, a more sophisticated approach was
required. In this study, we ﬁtted a structural model that
simpliﬁed the system without losing the biological inter-
pretation of the parameters. Mixed effects modelling
allowed for the addition of interindividual and interoc-
casion variability in model parameters, in addition to
residual variability. We were, therefore, able to simultan-
eously ﬁt the model to all patients and investigate covari-
ate–parameter relationships. Instead of exploring dose
recommendations by simulation, we aimed to optimise
the dose based on the target SDS and we minimised
deviations from this using least-squares regression.42 The
advantage of this approach, over testing competing
dosing regimens by simulation, is that once the optimal
target is deﬁned, the optimal dose needed to reach that
target is determined in a single step. Testing covariates
Figure 5 Incorporation of a disease activity index into dose
calculations allows an accurate prediction of circulating
insulin-like growth factor-1 (IGF-1). Utility function results
showing the effect of increasing sophistication on dose
scaling method. Scaling by weight, age group and Pediatric
Crohn’s Disease Activity Index score limits average IGF-1
concentrations in 93% of children to less than +2 SD score
(SDS). Solid lines are the target range of 0 to +2 SDS,
dashed lines are for reference −2 SDS and +2.5 SDS.
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for dose scaling is also simple with this method.
Furthermore, by using a large dataset of hypothetical
patients with real Crohn’s Disease demographics, we were
able to show how scaling dose by age, weight and PCDAI
score could adequately and safely correct IGF-1 (ﬁgure 5).
The goodness-of-ﬁt plots (ﬁgures 3B–E and f4) show
that the model predictions are an unbiased description
of the data and simulated data that are not signiﬁcantly
different to the observations (ﬁgure 3F). Furthermore,
covariate analysis showed that the disease severity
(PCDAI score) signiﬁcantly reduced endogenous synthe-
sis (Ksyn) rather than affecting IGF-1 clearance.
Variations in IGF-1 synthesis distinguish patients with
Crohn’s disease from children with GHIS.
A possible criticism of using PCDAI to quantify disease
in this context is that it includes growth as a marker of
inﬂammation, and it could be suggested that the depend-
ence of Ksyn on PCDAI might be due to the height vel-
ocity element of the index. Recently, the determinants of
the disease activity index have been separately analysed
for predictive value in deﬁned populations of children
with Crohn’s disease.43 Linear growth was discovered not
to be discriminatory. This report developed a new index,
the weighted Pediatric Crohn’s Disease Activity Index
(wPCDAI), based on these observations, which does not
include growth. We repeated our covariate modelling
with wPCDAI and showed that adding it to Ksyn reduced
parameter variability and signiﬁcantly improved model
ﬁt, in the same way as the standard PCDAI had. Thus, the
relationship between Ksyn and disease activity was due to
the objective measures of inﬂammation and not to the
growth component of the PCDAI calculation.
This report focused on the effects of IGF-1. As afore-
mentioned, hGH may also be of beneﬁt on the linear
growth of children with Crohn’s disease.36 It was not the
purpose of the present study to examine which therapy
would be more efﬁcacious; however, future studies com-
paring IGF-1 with hGH in a controlled randomised mul-
ticentre study are planned. This trial will also give us the
opportunity to test the dosing regimen derived from this
model presented in the present report on a wide sample
of children.
Patients and their support groups have long requested
more research into therapies that directly improve
growth in children whose inﬂammation cannot be con-
trolled. The present study shows that twice daily rhIGF-1
can enhance average circulating IGF-1 concentrations
into the upper normal range. The use of a utility function
from mathematical modelling allows paediatricians to
give rhIGF-1 without their entering an unphysiological
high range, hence reducing the increased risk of cancer.
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